Reply to the letter to the editor: genetic influence on visual outcomes of polypoidal choroidal vasculopathy

被引：0
作者：
Hata, Masayuki [1 ,2 ]
Tsujikawa, Akitaka [1 ,2 ]
Yoshimura, Nagahisa [1 ,2 ]
机构：
[1] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan
[2] Kagawa Univ, Fac Med, Dept Ophthalmol, 1750-1 Ikenobe,Miki Cho, Kagawa 7610793, Japan
来源：
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY | 2016年 / 254卷 / 05期
关键词：
Optical Coherence Tomography; Ranibizumab; Fluorescein Angiography; Visual Outcome; Indocyanine Green;
D O I：
10.1007/s00417-015-3163-3
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：1021 / 1022
页数：2
相关论文
共 50 条
  • [31] Prognostic factors of 2-year outcomes of ranibizumab therapy for polypoidal choroidal vasculopathy
    Hikichi, Taiichi
    Kitamei, Hirokuni
    Shioya, Shoko
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2015, 99 (06) : 817 - 822
  • [32] One-year outcomes of intravitreal brolucizumab injections in patients with polypoidal choroidal vasculopathy
    Ito, Arisa
    Maruyama-Inoue, Maiko
    Kitajima, Yoko
    Ikeda, Shoko
    Inoue, Tatsuya
    Kadonosono, Kazuaki
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [33] Five-year visual outcomes after anti-VEGF therapy with or without photodynamic therapy for polypoidal choroidal vasculopathy
    Miyata, Manabu
    Ooto, Sotaro
    Yamashiro, Kenji
    Tamura, Hiroshi
    Hata, Masayuki
    Ueda-Arakawa, Naoko
    Yoshikawa, Munemitsu
    Numa, Shogo
    Tsujikawa, Akitaka
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2019, 103 (05) : 617 - 622
  • [34] Pachychoroid-phenotype effects on 5-year visual outcomes of anti-VEGF monotherapy in polypoidal choroidal vasculopathy
    Shimizu, Yuichiro
    Miyata, Manabu
    Ooto, Sotaro
    Miyake, Masahiro
    Mori, Yuki
    Tamura, Hiroshi
    Ueda-Arakawa, Naoko
    Uji, Akihito
    Muraoka, Yuki
    Takahashi, Ayako
    Wakazono, Tomotaka
    Yamashiro, Kenji
    Hata, Masayuki
    Tsujikawa, Akitaka
    ACTA OPHTHALMOLOGICA, 2022, 100 (04) : E943 - E949
  • [35] Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy
    Mori, Ryusaburo
    Yuzawa, Mitsuko
    Lee, Zeon
    Haruyama, Miho
    Akaza, Eriko
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2010, 248 (09) : 1233 - 1239
  • [36] Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy
    Ryusaburo Mori
    Mitsuko Yuzawa
    Zeon Lee
    Miho Haruyama
    Eriko Akaza
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248 : 1233 - 1239
  • [37] Association between Vortex Vein Engorgement and Treatment Outcomes of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy
    Jeong, Areum
    Sagong, Min
    JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, 2021, 62 (10): : 1370 - 1380
  • [38] Short-Term Outcomes of Switching to Ranibizumab in Polypoidal Choroidal Vasculopathy Resistant to Aflibercept Therapy
    Jeon, Young-Joon
    Kim, Jae-Hui
    Kim, Jong-Woo
    Kim, Chul-Gu
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (24)
  • [39] Cost and Outcomes Analysis of Polypoidal Choroidal Vasculopathy (Aneurysmal Type 1 Neovascularization) Treatment Strategies
    Feng, Paula W.
    Lin, James
    Sakurada, Yoichi
    Yannuzzi, Nicolas A.
    Smiddy, William E.
    Chilakamarri, Priyanka
    Mehta, Nitish
    Modi, Yasha S.
    Parikh, Ravi
    JOURNAL OF VITREORETINAL DISEASES, 2021, 5 (03) : 227 - 231
  • [40] The 24-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy
    Nakai, Shunichiro
    Matsumiya, Wataru
    Keiko, Otsuka
    Miki, Akiko
    Nakamura, Makoto
    Honda, Shigeru
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2019, 63 (01) : 100 - 108
12345